These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6101863)

  • 1. Effect of thyrotropin-releasing hormone on ataxia of spinocerebellar degeneration.
    Sobue I; Yamamoto H; Konagaya M; Iida M; Takayanagi T
    Lancet; 1980 Feb; 1(8165):418-9. PubMed ID: 6101863
    [No Abstract]   [Full Text] [Related]  

  • 2. The pharmacological effect of thyrotropin-releasing hormone on ataxic mutant mice.
    Mano Y; Matsui K; Toyoshima E; Ando K
    Acta Neurol Scand; 1986 Apr; 73(4):352-8. PubMed ID: 3088901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute and chronic effects of thyrotropin-releasing hormone (TRH) on stabilogram in spinocerebellar degenerations.
    Yoshida M; Nakanishi T; Komatsu Y
    Tohoku J Exp Med; 1986 Mar; 148(3):327-31. PubMed ID: 3085285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Spinocerebellar degeneration].
    Takayanagi T
    Nihon Naika Gakkai Zasshi; 1993 Mar; 82(3):377-80. PubMed ID: 8315331
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of DN-1417 on ataxia in Rolling mouse Nagoya and Staggerer mouse in comparison with the effect of TRH].
    Matsui K; Mano Y; Ando K
    Yakubutsu Seishin Kodo; 1986 Jun; 6(2):281-3. PubMed ID: 3096012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ameliorating effect of rovatirelin on the ataxia in rolling mouse Nagoya.
    Ijiro T; Yaguchi A; Yokoyama A; Abe Y; Kiguchi S
    Eur J Pharmacol; 2020 Sep; 882():173271. PubMed ID: 32534077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bedside and electro-oculographic analysis of abnormal ocular movements in spinocerebellar degenerations: effects of thyrotropin-releasing hormone.
    Yamamoto H; Saito S; Sobue I
    Neurology; 1988 Jan; 38(1):110-4. PubMed ID: 3122069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Spinocerebellar degenerations].
    Sobue I
    Nihon Naika Gakkai Zasshi; 1984 Oct; 73(10):1415-31. PubMed ID: 6440937
    [No Abstract]   [Full Text] [Related]  

  • 9. Ataxia-ameliorating effects of YM-14673, a potent analog of thyrotropin releasing hormone, in ataxic mutant mice.
    Matsui K; Wada K; Kwak S
    Eur J Pharmacol; 1994 Mar; 254(3):295-7. PubMed ID: 8013566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motor disabilities and effects of thyrotropin-releasing hormone on ataxia of spinocerebellar degeneration.
    Kimura I; Ohtomo H; Kogure K
    Tohoku J Exp Med; 1983 Apr; 139(4):331-7. PubMed ID: 6408760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The influence of thyrotropin releasing hormone on the abnormal ocular movements of the brainstem involvement].
    Yamamoto H; Mizuno Y; Takayanagi T; Iida M; Sobue I
    Rinsho Shinkeigaku; 1985 Apr; 25(4):385-92. PubMed ID: 3926369
    [No Abstract]   [Full Text] [Related]  

  • 12. [Chronic experimentation with TRH administered intramuscularly in spinocerebellar degeneration. Double-blind cross-over study in 30 subjects].
    Filla A; De Michele G; Di Martino L; Mengano A; Iorio L; Maggio MA; Campanella G
    Riv Neurol; 1989; 59(2):83-8. PubMed ID: 2505370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of YM-14673, a new thyrotropin releasing hormone analogue, on ataxic gait in cytosine arabinoside-treated mice.
    Yamamoto M; Shimizu M
    Eur J Pharmacol; 1989 Aug; 166(3):545-7. PubMed ID: 2509218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Amine metabolites in cerebrospinal fluids and thyrotropin releasing hormone in spinocerebellar degeneration].
    Arai M
    Rinsho Shinkeigaku; 1988 Jun; 28(6):595-604. PubMed ID: 2466598
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of thyrotropin-releasing hormone in the treatment of cerebellar ataxia.
    Takeuchi Y; Fujiwara K; Ishimura K; Shimada Y; Ochi M; Yoshioka H; Sawada T
    Pediatr Neurol; 1989; 5(2):107-10. PubMed ID: 2469426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effect of thyrotropin releasing hormone (TRH) on regional cerebral blood flow in spinocerebellar degeneration using 3DSRT.
    Kimura N; Kumamoto T; Masuda T; Nomura Y; Hanaoka T; Hazama Y; Okazaki T; Arakawa R
    J Neurol Sci; 2009 Jun; 281(1-2):93-8. PubMed ID: 19286195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spinocerebellar degeneration and neuropeptides.
    Matsuoka Y; Sakurai N
    Jpn J Med; 1989; 28(6):791-3. PubMed ID: 2517445
    [No Abstract]   [Full Text] [Related]  

  • 18. Spinocerebellar degenerations--clinical aspects and new treatment of ataxia.
    Sobue I
    Jpn J Med; 1985 Feb; 24(1):62-7. PubMed ID: 3923240
    [No Abstract]   [Full Text] [Related]  

  • 19. [Spinocerebellar degeneration and neuropeptides].
    Matsuoka Y; Sakurai N
    Nihon Naika Gakkai Zasshi; 1989 Dec; 78(12):1705-8. PubMed ID: 2516527
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical manifestations and thyrotropin releasing hormone therapy in cerebellar degenerations.
    Wang HC; Chiu HC
    Zhonghua Yi Xue Za Zhi (Taipei); 1991 Mar; 47(3):161-8. PubMed ID: 1848143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.